Download - Background
![Page 1: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/1.jpg)
Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization
between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal
antibody to the epidermal growth factor receptor (EGF-r) : an Eastern Cooperative Oncology
Group Study (E8200)
B. A. Burtness, M. Powell, J. Berlin, D. Liles, A. Chapman, E. Mitchell, A. B. Benson, Eastern Cooperative Oncology
Group
Fox Chase Cancer Center, Philadelphia; Dana-Farber Cancer Institute, Boston; Vanderbilt University, Nashville; East Carolina University School of
Medicine , Greenville; Thomas Jefferson University, Philadelphia; Northwestern University, Chicago
![Page 2: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/2.jpg)
Background
• Gemcitabine is standard for metastatic pancreatic cancer– median survivals of < 6 mo
• Second cytotoxic or biologic agents do not substantially advance survival
• EGFR is expressed on PC• A phase II trial of gemcitabine plus
cetuximab resulted in median survival 6.7 and 1 year survival 32.5%
![Page 3: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/3.jpg)
Irinotecan/Docetaxel Phase II
• Irinotecan and docetaxel are synergistic in preclinical models• Cetuximab/irinotecan active in irinotecan-refractory colon
cancer• A phase II trial of the Murren regimen of weekly
irinotecan/docetaxel (I/D) chemotherapy reported a median survival for metastatic patients (pts) of 9 mo and RR 27%
• We conducted this randomized phase II trial to confirm the activity of this non-gemcitabine regimen, and determine whether combining it with cetuximab was feasible and active
![Page 4: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/4.jpg)
E8200 Eligibility
• Histologically confirmed adenocarcinoma of the pancreas that is metastatic
• No prior chemotherapy for metastatic disease
• Prior gemcitabine or 5FU in the neoadjuvant or adjuvant setting permitted if > 6 months have elapsed
• ECOG 0 or 1
![Page 5: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/5.jpg)
E8200 Eligibility
• AST ≤ 2.5 x ULN if alk phos normal• Alk phos ≤ 4 x ULN if transaminases
normal• Transaminases > 1.5 x ULN and alk phos
> 2.5 x ULN -> Ineligible• Tissue from core biopsy or open
procedure available for IHC (this requirement was removed by amendment midway through the trial to ease accrual)
![Page 6: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/6.jpg)
E8200 Study Design
• Dexamethasone premedication• Docetaxel 35 mg/m2 followed by irinotecan 50
mg/m2 weekly x 4, q 6 weeks• Randomized phase II, 2 arms:
– Irinotecan/docetaxel– Irinotecan/docetaxel + cetuximab loading dose of 400
mg/m2 followed by 250 mg/m2 weekly
• All pts receive prophylactic enoxaparin if not on therapeutic anticoagulation
![Page 7: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/7.jpg)
Statistical Considerations
• Primary endpoint response in each arm• Secondary endpoints
– Time to progression– Overall survival– Toxicity– Rate of thromboembolic events with use of
prophylactic enoxaparin– Prospective determination of EGFR expression in
population of patients with metastatic pancreatic cancer
![Page 8: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/8.jpg)
Statistical Considerations
• Null hypothesis is RR 5%
• Response rate of interest 20%
• 2 responses in first 22 patients required for either arm to proceed to second stage
• Accrual to Arm B allowed for 3 patients to be replaced in the event of hypersensitivity to cetuximab
![Page 9: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/9.jpg)
Disease Evaluation
• CT scan and tumor markers at baseline.
• Reevaluate q 2 cycles (ie after 12 weeks).
• Patients attaining objective response had CT scan and tumor markers repeated after one further cycle of chemotherapy (ie at 18 weeks).
![Page 10: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/10.jpg)
E8200
• Final accrual 94 patients from 7/31/03 to 8/23/06
• 8 patients were ineligible– Died prior to receiving therapy, prior chemo,
outdated scans, laboratory results out of range, no measurable disease
![Page 11: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/11.jpg)
Demographics Treatment Arm
A (N=43) B (N=43) Total
(N=86)
N % N % N %
Sex
Male 23 53.5 37 86.0 60 70
Female 20 46.5 6 14.0 26 30
PS
0 15 34.9 19 44.2 34 40
1 28 65.1 24 55.8 52 60
Age
Treatment Arm N Mean Std Dev Minimum Median Maximum
A 43 58.1 9.6 41.0 60.4 77.1
B 43 59.6 9.0 41.0 60.6 74.2
Total 86 58.9 9.3 41.0 60.5 77.1
![Page 12: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/12.jpg)
Treatment Information
A B
Mean cycle# 2.6 3.3
Median cycle# 2 2
Pts with >4 cycles 9.3% 20.9%
![Page 13: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/13.jpg)
Common Grade 3/4 Toxicity A BN % N %46 45
Neutrophils 11 (24) 14 (31) Fatigue 10 (22) 8 (18)Anorexia 8 (17) 4 (9)Nausea 14 (30) 9 (20)Vomiting 6 (13) 9 (20)Diarrhea 14 (30) 20 (44)Hyperglycemia 3 (7) 5 (11)Hypomagnesemia 0 3 (7)Neutropenic Fever/Inf 3 (6) 4 (9)
Worst 33 (72) 35 (78)
![Page 14: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/14.jpg)
Bleeding Events
A BN % N %
46 45Epistaxis, gd 1 0 7 (16)Rectal bldg, gd 1 0 1 (2)Hematemesis, gd 1 2 (4) 0Hematuria, gd 2 0 1 (2)Hemorrhage/other, gd1 0 1 (2)
![Page 15: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/15.jpg)
Treatment-Related Death
A BN 46 45
Neutropenia with
fever or infection 1 1
Diarrhea with sepsis 1
Total 2.2% 4.4%
![Page 16: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/16.jpg)
Response
A B
Unknown 4.7% 0%
PR 2.3% 7%
SD 39.5% 37.2%
PD 34.9% 25.6%
Uneval 18.6% 30.2%
![Page 17: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/17.jpg)
Progression-Free Survival
A B
Data available, N= 41 38
Median PFS 2.8 4.5
95% CI 2.4,4.8 2.7,5.3
![Page 18: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/18.jpg)
Treatment Arm ALIVEDEAD MEDIANTOTALA 41 37 4 2.8B 38 35 3 4.5
Survival Probability
PFS by Treatment Arm - E8200
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Progression-Free Survival (Months)
0 2 4 6 8 10 12 14
![Page 19: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/19.jpg)
Overall SurvivalKaplan-Meier
A B
Median 6.5 5.3
95% CI 5.3-8.6 4.4-9.5
Known to have died 86.1% 93%
![Page 20: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/20.jpg)
Treatment Arm ALIVEDEAD MEDIANTOTALA 43 37 6 6.5B 43 40 3 5.3
Survival Probability
Overall Survival by Treatment Arm - E8200
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Overall Survival Time in Months
0 5 10 15 20 25 30 35
![Page 21: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/21.jpg)
50% Decline in CA19-9
A BN 37 3650% drop 11 (30%) 14 (39%)Median PFS
without 50% drop 2.6m (2.3,3.9) 2.9m (2.2,4.9)with 50% drop 4.9m (2.9,7.2) 5.7m (5.1,8.3)
Median OS without 50% drop 5.8m (4.1-7.4) 4.4 (3.7-11)with 50% drop 9.9m (6.5,11.9) 9.5 (5.0,15.5)
![Page 22: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/22.jpg)
CA19-9-Pooled Data
Bsl CA19-9 < median PFS 5.1m (2.9, 5.6) > median PFS 2.6m (2.3,2.9) p*=0.048
Median PFSwithout 50% drop 2.6m (2.3,2.9)with 50% drop 5.3m (4.8,6.5) p=0.001
Median OS without 50% drop 5.6m (4.1-7.4)with 50% drop 9.9m (6.5,12) p=0.02
*2-sided log-rank test
![Page 23: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/23.jpg)
ALIVEDEAD MEDIANTOTALAbove Median Baseline CA19-9 No 28 24 4 5.1Yes 26 24 2 2.6
Survival Probability
p=0.048
PFS by Above / Below Median Baseline CA19-9: E8200 Pooled Data
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Progression-Free Survival (Months)
0 2 4 6 8 10 12 14
![Page 24: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/24.jpg)
ALIVEDEAD MEDIANTOTALAbove Median Baseline CA19-9 No 16 14 2 6.1Yes 48 41 7 5.3
Survival Probability
p=0.51
OS by Above / Below Median Baseline CA19-9: E8200 Pooled Data
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Overall Survival (Months)
0 5 10 15 20 25 30 35
![Page 25: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/25.jpg)
ALIVEDEAD MEDIANTOTAL50% Drop in CA19-9 No 43 39 4 2.6Yes 24 21 3 5.3
Survival Probability
p=0.002
PFS by 50% Drop From Baseline CA19-9: E8200 Pooled Data
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Progression-Free Survival (Months)
0 2 4 6 8 10 12 14
![Page 26: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/26.jpg)
ALIVEDEAD MEDIANTOTAL50% Drop in CA19-9 No 48 42 6 5.6Yes 25 22 3 9.9
Survival Probability
p=0.020
OS by 50% Drop From Baseline CA19-9: E8200 Pooled Data
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Overall Survival Time in Months
0 5 10 15 20 25 30 35
![Page 27: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/27.jpg)
ALIVEEGFR Intensity/Density DEAD MEDIANTOTALIntensity = 3+ and Density > 50%15 9 6 4.5 Otherwise 45 39 6 4.2
Survival Probability
p=0.27
PFS by EGFR Intensity/Density: E8200 Pooled Data
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Progression-Free Survival (Months)
0 2 4 6 8 10 12 14
![Page 28: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/28.jpg)
ALIVEEGFR Intensity/Density DEAD MEDIANTOTALIntensity = 3+ and Density > 50%15 12 3 5.0 Otherwise 45 42 3 8.4
Survival Probability
p=0.87
Overall Survival by EGFR Intensity/Density: E8200 Pooled Data
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Overall Survival Time in Months
0 5 10 15 20 25 30 35
![Page 29: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/29.jpg)
ALIVEDEAD MEDIANTOTALClot No 66 57 9 3.9Yes 19 14 5 2.9
Survival Probability
p=0.91
PFS by Clot: E8200 Pooled Data
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Progression-Free Survival (Months)0 2 4 6 8 10 12 14
![Page 30: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/30.jpg)
ALIVEDEAD MEDIANTOTALClot No 66 60 6 6.5Yes 19 16 3 6.8
Survival Probability
p=0.87
Overall Survival by Clot: E8200 Pooled Data
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Overall Survival (Months)
0 5 10 15 20 25 30 35
![Page 31: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/31.jpg)
Conclusions
• Non-gemcitabine containing chemotherapy has activity in metastatic pancreatic cancer
• Response rate by RECIST on a 12 week reassessment schedule is not a useful endpoint in pancreatic cancer in the cooperative group setting – 19-30% unevaluable
• 50% drop in CA19-9 correlates with PFS and OS and may represent a more reproducible endpoint in cooperative group trials in metastatic pancreatic cancer
![Page 32: Background](https://reader035.vdocuments.net/reader035/viewer/2022062408/56813b70550346895da478f4/html5/thumbnails/32.jpg)
Conclusions
• The routine use of prophylactic LWM heparin is feasible in patients with metastatic pancreatic cancer, with a low rate of hemorrhage on study
• Toxicity of irinotecan/docetaxel with or without cetuximab is high – Grade 3/4 diarrhea 33-40%– Treatment related death 2-4%– UGT1A1 testing not performed